Drug Profile
Research programme: prostaglandin mimetics - York Pharma
Alternative Names: Respiratory antiviral programme - York Pharma; RPL 208Latest Information Update: 04 Apr 2011
Price :
$50
*
At a glance
- Originator York Pharma
- Class
- Mechanism of Action Prostaglandin agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Viral infections
Most Recent Events
- 13 Jun 2007 Preclinical trials in Cancer in United Kingdom (unspecified route)
- 13 Jun 2007 Preclinical trials in Viral infections in United Kingdom (unspecified route)